NeuroBo Pharmaceuticals appoints Dr. James Tursi to its Board of Directors

– USA, MA –  NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced the appointment of Dr. James Tursi (M.D.) to its Board of Directors, effective November 1, 2023. Dr. Tursi will also serve as a member of the Board’s Nominating and Corporate Governance Committee.

“James is a proven leader, with nearly 20 years in the pharmaceutical industry and over 30 total years of medical experience. Having served as both chief medical officer and chief scientific officer of a number of companies, over the years, James’ expertise will be valuable as we continue to advance the clinical development of our two unique and promising cardiometabolic assets which address the large nonalcoholic steatohepatitis and obesity markets,” said Board Chairman,  Andrew Koven.

About Dr. James Tursi

Dr. James Tursi is currently EVP of Global Research and Development for Endo International plc, which he joined in January 2022. Previously, from April 2020 until January 2022, Dr. Tursi was CSO U.S. for Ferring Pharmaceuticals. From August 2018 until April 2020, Dr. Tursi served as CMO and EVP of Research and Development for Antares Pharma Inc. Earlier in his career, Dr. Tursi was the CMO of Aralez Pharmaceuticals Inc., CMO and VP of Clinical Research and Development for Auxilium Pharmaceuticals, Inc., and held positions of increasing responsibility at GlaxoSmithKline plc and Procter & Gamble Pharmaceuticals.

Dr. Tursi added, “I am honored to join the NeuroBo Board of Directors during such a transformative stage for the Company, especially with multiple near-term milestones on the horizon, which could meaningfully drive shareholder value going forward. As such, I look forward to working closely with the NeuroBo leadership team and my fellow Directors to maximize the potential for the Company’s next generation pharmaceuticals to treat cardiometabolic diseases.”

Dr. Tursi practiced medicine and surgery for over 10 years and created a medical education company, I Will Pass, which assisted physicians in the process of board certification. He earned a Bachelor of Science degree in chemistry and biology from Ursinus College; a Doctor of Medicine from Medical College of Pennsylvania and completed his residency in Gynecology and Obstetrics at the Johns Hopkins Hospital.

About NeuroBo Pharmaceuticals

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Non-Alcoholic Steatohepatitis and Type 2 Diabetes Mellitus, and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 agonist, which promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin analog that acts as a glucagon-like peptide-1 receptor and glucagon receptor dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.